PeptideNerds

Cagrilintide

GLP-1 / Weight Loss Clinical Trials moderate evidence Track This Protocol
Alejandro Reyes

Written by Alejandro Reyes

Founder & Lead Researcher

PN

Reviewed by Peptide Nerds Editorial · Updated April 2026

Key Takeaway

Cagrilintide is a long-acting amylin analog being developed by Novo Nordisk, studied in combination with semaglutide (CagriSema) for enhanced weight loss.

Quick Facts
Type GLP-1 / Weight Loss
FDA Status Clinical Trials
Evidence Level Moderate
Typical Dose 2.4 mg weekly (in combination)
Frequency Once weekly
Key Goals weight-loss

How it works

Mimics the hormone amylin, which is co-secreted with insulin. Reduces appetite through hypothalamic signaling and slows gastric emptying via a pathway independent of GLP-1.

Benefits

  • Complementary mechanism to GLP-1 agonists
  • CagriSema combination shows greater weight loss than semaglutide alone

Side effects

  • Nausea
  • Injection site reactions

Dosing protocol

Typical Dose

2.4 mg weekly (in combination)

Frequency

Once weekly

Studied primarily in combination with semaglutide (CagriSema).

Deeper on Cagrilintide

Full breakdowns of every part of the Cagrilintide research base.

What you will need

Basic supplies for reconstitution and subcutaneous injection.

This page contains affiliate links. Learn more

Get the Cagrilintide cheat sheet

Dosing quick-reference, key studies, and side effect management — in your inbox.

Get the Cagrilintide cheat sheet

Dosing quick-reference, key studies, and side effect management — in your inbox.

Compare Cagrilintide

Related peptides

Get the Peptide Starter Kit (free)

Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.

Medical Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional medical consultation, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol.